 Medill Reports: Chicago | Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter ... MarketWatch (press release) Abbott's partnership with Biogen Idec includes development of a novel, next-generation antibody, daclizumab, which is currently in Phase 3 clinical trials for MS. Additionally, Abbott recently announced positive results from a Phase 3 trial evaluating ... Abbott Beats, Raises Outlook - Analyst Blog |
